Resurgent and Emerging Infectious Diseases,1568-1041 ; 1
내용주기
1 ??Introduction -- 2 ??The epidemiology of multidrug-resistant tuberculosis in the United States and other established market economies -- 3 ??Epidemiology of multidrug-resistant tuberculosis in low- and middle-income countries -- 4 ??The interaction of human immunodeficiency virus and multidrug-resistant Mycobacterium tuberculosis -- 5 ??Clinical mismanagement and other factors producing antituberculosis drug resistance -- 6 ??The molecular mechanisms of drug resistance in Mycobacterium tuberculosis -- 7 ??DOTS and multidrug-resistant tuberculosis -- 8 ??Conventional methods for antimicrobial susceptibility testing of Mycobacterium tuberculosis -- 9 ??Novel rapid antimicrobial susceptibility tests for Mycobacterium tuberculosis -- 10 ??Pharmacology of the second-line antituberculosis drugs -- 11 ??Treatment of multidrug-resistant tuberculosis -- 12 ??Treatment of multidrug-resistant tuberculosis in developing countries -- 13 ??Treatment of outcome of multidrug-resistant tuberculosis -- 14 ??Chemoprophylaxis and BCG in contacts of multidrug- resistant tuberculosis -- 15 ??Multidrug-resistant tuberculosis and the health care worker -- 16 ??The development of new chemotherapeutics for multidrug-resistant tuberculosis -- 17 ??Population dynamics and control of multidrug-resistant tuberculosis -- 18 ??Administrative, engineering, and personal protective measures for controlling Mycobacterium tuberculosis -- 19 ??Making DOTS-Plus work.
![Multidrug-resistant Tuberculosis [electronic resource]](https://ymlib.yonsei.ac.kr/wp-content/uploads/remote/books/9789401140843.jpg)